Q2 2025 Earnings Forecast for Hologic, Inc. Issued By Zacks Research (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Stock analysts at Zacks Research upped their Q2 2025 EPS estimates for shares of Hologic in a report issued on Wednesday, April 10th. Zacks Research analyst R. Anand now forecasts that the medical equipment provider will post earnings per share of $1.11 for the quarter, up from their prior estimate of $1.10. The consensus estimate for Hologic’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for Hologic’s FY2025 earnings at $4.28 EPS.

A number of other equities analysts have also commented on HOLX. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Wednesday, April 10th. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Raymond James lifted their price target on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Finally, UBS Group lifted their price target on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $87.00.

Hologic Price Performance

NASDAQ:HOLX opened at $77.33 on Monday. Hologic has a 52 week low of $64.02 and a 52 week high of $87.88. The firm has a market cap of $18.15 billion, a price-to-earnings ratio of 36.65, a P/E/G ratio of 2.62 and a beta of 1.00. The firm’s 50-day simple moving average is $75.53 and its 200 day simple moving average is $72.37. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. Hologic’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.07 EPS.

Institutional Trading of Hologic

Several hedge funds have recently modified their holdings of HOLX. Macquarie Group Ltd. increased its stake in shares of Hologic by 227.2% in the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after acquiring an additional 4,363,687 shares in the last quarter. Norges Bank bought a new stake in shares of Hologic in the 4th quarter valued at $217,529,000. The Manufacturers Life Insurance Company increased its stake in shares of Hologic by 117.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after acquiring an additional 1,168,564 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Hologic by 110.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,896,174 shares of the medical equipment provider’s stock valued at $145,664,000 after acquiring an additional 995,854 shares in the last quarter. Finally, Qube Research & Technologies Ltd increased its stake in shares of Hologic by 117.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock valued at $95,651,000 after acquiring an additional 743,557 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling

In other news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares in the company, valued at approximately $7,793,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Insiders have sold a total of 32,846 shares of company stock worth $2,473,443 in the last ninety days. Company insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.